SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-268165
Filing Date
2023-11-01
Accepted
2023-11-01 16:01:34
Documents
14
Period of Report
2023-11-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d518702d8k.htm   iXBRL 8-K 25490
2 EX-99.1 d518702dex991.htm EX-99.1 71721
6 GRAPHIC g518702g1031220816894.jpg GRAPHIC 2414
  Complete submission text file 0001193125-23-268165.txt   235917

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nmra-20231101.xsd EX-101.SCH 2877
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nmra-20231101_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nmra-20231101_pre.xml EX-101.PRE 11725
8 EXTRACTED XBRL INSTANCE DOCUMENT d518702d8k_htm.xml XML 3470
Mailing Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472 (857) 760-0900
Neumora Therapeutics, Inc. (Filer) CIK: 0001885522 (see all company filings)

IRS No.: 844367680 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41802 | Film No.: 231368093
SIC: 2836 Biological Products, (No Diagnostic Substances)